WallStreetZenWallStreetZen

NASDAQ: AUPH
Aurinia Pharmaceuticals Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Aurinia Pharmaceuticals earnings were $314.3M for the trailing 12 months ending Sep 30, 2026, with 306.9% growth year over year. The latest AUPH earnings report on Sep 30, 2026 announced Q3 2026 earnings of $31.7M, down 15.3% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, AUPH reported annual earnings of $287.2M, with 4,893.1% growth.

AUPH past earnings growth

How has AUPH's earnings growth performed historically?

Company
306.9%
Industry
41.02%
Market
93.64%
AUPH's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
AUPH's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Market Performance
AUPH's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

AUPH earnings history

Current Revenue
$321.7M
Current Earnings
$314.3M
Current Profit Margin
97.7%

AUPH Return on Equity

Current Company
51.9%
Current Industry
-19.6%
Current Market
39.9%
AUPH's Return on Equity (51.9%)... subscribe to Premium to read more.
High Return on Equity Performance

AUPH Return on Assets

Current Company
40.6%
Current Industry
2.1%
AUPH is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when AUPH announces earnings.

AUPH Return on Capital Employed

Current Company
23.43%
Current Industry
-0.1%
AUPH has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

AUPH vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
AUPH$190.35M$314.27M+306.90%$2.36
VERA-$393.04M-$401.90MN/A-$5.86
PVLA-$52.51M-$61.70MN/A-$4.83
BCRX-$304.20M-$384.67MN/A-$1.44
XNCR-$123.60M-$163.33MN/A-$2.17
View Top Biotech Stocks

Aurinia Pharmaceuticals Earnings Reports & History FAQ

What were Aurinia Pharmaceuticals's earnings last quarter?

On AUPH's earnings call on Oct 30, 2026, Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q3 2026 earnings per share (EPS) of $0.24, up 0% year over year. Total AUPH earnings for the quarter were $31.70 million. In the same quarter last year, Aurinia Pharmaceuticals's earnings per share (EPS) was $0.24.

If you're new to stock investing, here's how to buy Aurinia Pharmaceuticals stock.

Is Aurinia Pharmaceuticals profitable or losing money?

As of the last Aurinia Pharmaceuticals earnings report, Aurinia Pharmaceuticals is currently profitable. Aurinia Pharmaceuticals's net profit (also called net income) for the twelve months ending Sep 30, 2026 was $314.27 million, a 303.75% increase year over year.

What was AUPH's earnings growth in the past year?

As of Aurinia Pharmaceuticals's earnings date in Oct 30, 2026, Aurinia Pharmaceuticals's earnings has grown 306.9% year over year. This is 265.87 percentage points higher than the US Biotechnology industry earnings growth rate of 41.02%. AUPH earnings in the past year totalled $314.27 million.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.